Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Lin, Jennie ^a   Reilly, Muredach P ^b   Terembula, Karen ^b   Wilson, F Perry ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CREATININE; LIPOPROTEIN A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MILD RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RACE DIFFERENCE; ATHEROSCLEROSIS; BLOOD; COMPLICATION; KIDNEY DISEASE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY;

ADULT; AGED; ALBUMINURIA; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TRIGLYCERIDES;

EID: 84918574834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114397     Document Type: Article

References (56)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047. doi:10.1001/jama.298.17.2038.
2. Sarnak MJ (2003) Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169. doi:10.1161/01.CIR.0000095676.90936.80.
3. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, et al. (2003) Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41: 47-55.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305. doi:10.1056/NEJMoa041031.
5. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, et al. (2013) Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. Journal of the American Society of Nephrology 24: 302-308. doi:10.1681/ASN.2012070718.
6. Haffner SM, Lehto S, Rönnemaa T, Pyö rä lä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234. doi:10.1056/NEJM199807233390404.
7. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, et al. (2013) Rates of Complications and Mortality in Older Patients With Diabetes Mellitus. JAMA Intern Med. doi:10.1001/jamainternmed.2013.12956.
8. Fox CS, Coady S, Sorlie PD, D'Agostino RB, Pencina MJ, et al. (2007) Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study. Circulation 115: 1544-1550. doi:10.1161/CIRCULATIONAHA.106.658948.
9. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2014) Heart Disease and Stroke Statistics-2014 Update: A Report From the American Heart Association. Circulation 129: E28-e292. doi:10.1161/01.cir.0000441139.02102.80.
10. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591. doi:10.1056/NEJMoa0706245.
11. KDIGO (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int. doi:10.1038/ki.2014.31.
12. KDOQI (2007) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49: S12-S154. doi:10.1053/j.ajkd.2006.12.005.
13. Joosen IA, Schiphof F, Versteylen MO, Laufer EM, Winkens MH, et al. (2012) Relation between Mild to Moderate Chronic Kidney Disease and Coronary Artery Disease Determined with Coronary CT Angiography. PLoS ONE 7: E47267. doi:10.1371/journal.pone.0047267.t004.
14. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Tamura H, et al. (2011) Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Nephrology Dialysis Transplantation 26: 2906-2911. doi:10.1093/ndt/gfq820.
15. National Kidney Foundation (2012) KDOQI CLINICAL PRACTICE GUIDELINE FOR DIABETES AND CKD: 2012 UPDATE. YAJKD 60: 850-886. doi:10.1053/j.ajkd.2012.07.005.
16. De Boer IH, Astor BC, Kramer H, Palmas W, Rudser K, et al. (2008) Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atheroslcerosis (MESA). Atherosclerosis 197: 407-414. doi:10.1016/j.atherosclerosis.2007.06.018.
17. Vaziri ND (2006) Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272. doi:10.1152/ajprenal.00099.2005.
18. Keane WF, Tomassini JE, Neff DR (2013) Lipid abnormalities in patients with chronic kidney disease: Implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb 20: 123-133.
19. Pennell P, Leclercq B, Delahunty MI, Walters BAJ (2006) The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease. Clin Nephrol 66: 336-347.
20. Attman PO, Samuelsson O, Alaupovic P (1993) Lipoprotein metabolism and renal failure. YAJKD 21: 573-592.
21. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, et al. (2013) Discovery and refinement of loci associated with lipid levels. Nat Genet 45: 1274-1283. doi:10.1038/ng.2797.
22. Nakamura T, Obata J-E, Hirano M, Kitta Y, Fujioka D, et al. (2011) Atherosclerosis. Atherosclerosis 218: 163-167. doi:10.1016/j.atherosclerosis.2011.04.040.
23. Lamprea-Montealegre JA, McClelland RL, Astor BC, Matsushita K, Shlipak M, et al. (2013) Chronic Kidney Disease, Plasma Lipoproteins, and Coronary Artery Calcium Incidence: The Multi-Ethnic Study of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 33: 652-658. doi:10.1161/ATVBAHA.112.300624.
24. Attman P-O, Samuelsson O (2009) Dyslipidemia of kidney disease. Current Opinion in Lipidology 20: 293-299. doi:10.1097/MOL.0b013e32832dd832.
25. Ooi EMM, Chan DT, Watts GF, Chan DC, Ng TWK, et al. (2011) Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. The Journal of Lipid Research 52: 794-800. doi:10.1194/jlr.M011163.
26. Wang X, Belani S, Coyne DW, Fabbrini E, Reeds DN, et al. (2012) Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease. Cardiorenal Med 2: 57-65. doi:10.1159/000335509.
27. Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, et al. (2009) Chronic kidney disease delays VLDLapoB-100 particle catabolism: Potential role of apolipoprotein C-III. The Journal of Lipid Research 50: 2524-2531. doi:10.1194/jlr.P900003-JLR200.
28. Holzmann MJ, Jungner I, Walldius G, Ivert T, Nordqvist T, et al. (2012) Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Ann Med 44: 262-270. doi:10.3109/07853890.2010.532153.
29. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P (1998) The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13: 2833-2841.
30. Attman PO, Samuelsson O, Alaupovic P (2011) The effect of decreasing renal function on lipoprotein profiles. Nephrology Dialysis Transplantation 26: 2572-2575. doi:10.1093/ndt/gfq762.
31. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, et al. (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-2528. doi:10.1056/NEJMoa0902604.
32. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, et al. (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423. doi:10.1001/jama.2009.1063.
33. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, et al. (2012) Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 125: 241-249. doi:10.1161/CIRCULATIONAHA.111.045120.
34. Tsimikas S, Hall JL (2012) Lipoprotein(a) as a Potential CausalGenetic Risk Factor of Cardiovascular Disease. J Am Coll Cardiol 60: 716-721. doi:10.1016/j.jacc.2012.04.038.
35. Anderson JL, Knight S, May HT, Home BD, Bair TL, et al. (2013) Validation and Quanti. The American Journal of Cardiology 112: 799-804. doi:10.1016/j.amjcard.2013.05.009.
36. Jacobson TA (2013) Lipoprotein(a), Cardiovascular Disease, and Contemporary Management. Mayo Clinic Proceedings 88: 1294-1311. doi:10.1016/j.mayocp.2013.09.003.
37. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331-2339. doi:10.1001/jama.2009.801.
38. Kronenberg F, Utermann G (2012) Lipoprotein(a): Resurrected by genetics. Journal of Internal Medicine 273: 6-30. doi:10.1111/j.1365-2796.2012.02592.x.
39. Kronenberg F, Kuen E, Ritz E, Junker R, Kö nig P, et al. (2000) Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11: 105-115.
40. O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, et al. (2013) Accepted Manuscript. J Am Coll Cardiol: 1-43. doi:10.1016/j.jacc.2013.09.042.
41. Sechi LA, Zingaro L, Catena C, Perin A, De Marchi S, et al. (1999) Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 56: 1049-1057. doi:10.1046/j.1523-1755.1999.00621.x.
42. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, et al. (2004) Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 89: 3872-3878. doi:10.1210/jc.2003-031676.
43. Lilly SM, Qasim AN, Mulvey CK, Churchill TW, Reilly MP, et al. (2013) Non-compressible arterial disease and the risk of coronary calcification in type-2 diabetes. Atherosclerosis 230: 17-22. doi:10.1016/j.atherosclerosis.2013.06.004.
44. Qasim AN, Rafeek H, Rasania SP, Churchill TW, Yang W, et al. (2013) Atherosclerosis. Atherosclerosis 226: 419-424. doi:10.1016/j.atherosclerosis.2012.11.011.
45. Martin SS, Qasim AN, Wolfe M, Clair CS, Schwartz S, et al. (2011) Comparison of High-Density Lipoprotein Cholesterol to Apolipoprotein A-I and A-II to Predict Coronary Calcium and the Effect of Insulin Resistance. The American Journal of Cardiology 107: 393-398. doi:10.1016/j.amjcard.2010.09.033.
46. Mulvey CK, McNeill AM, Girman CJ, Churchill TW, Terembula K, et al. (2014) Differential Associations of Oral Glucose Tolerance Test-Derived Measures of Insulin Sensitivity and Pancreatic b-Cell Function With Coronary Artery Calcification and Microalbuminuria in Type 2 Diabetes. Diabetes Care 37: 124-133. doi:10.2337/dc12-1880.
47. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
48. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
49. Willey JZ, Rodriguez CJ, Carlino RF, Moon YP, Paik MC, et al. (2011) Race-ethnic differences in the association between lipid profile components and risk of myocardial infarction: The Northern Manhattan Study. American Heart Journal 161: 886-892. doi:10.1016/j.ahj.2011.01.018.
50. Uhlig K, Wang S-R, Beck GJ, Kusek JW, Marcovina SM, et al. (2005) Factors associated with lipoprotein(a) in chronic kidney disease. American Journal of Kidney Diseases 45: 28-38. doi:10.1053/j.ajkd.2004.08.043.
51. Elosua R, Sayols-Baixeras S, Llu?-Ganella C, Lucas G (2014) Pathogenesis of coronary artery disease: Focus on genetic risk factors and identification of genetic variants. TACG doi:10.2147/TACG.S35301
52. Rosas S, Joffe M, Wolfe M, Brayman K, Rader DJ (2008) Effects of Renal Replacement Therapy on Plasma Lipoprotein(a) Levels. Am J Nephrol 28: 361-365. doi:10.1159/000112225.
53. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, et al. (1997) Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. The Journal of Lipid Research 38: 1755-1763.
54. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, et al. (1996) Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure. Nephrol Dial Transplant 11: 2237-2243.
55. Rahman M, Yang W, Akkina S, Alper A, Anderson AH, et al. (2014) Relation of Serum Lipids and Lipoproteins with Progression of CKD: The CRIC Study. Clinical Journal of the American Society of Nephrology. doi:10.2215/CJN.09320913.
56. Chan DC, Pang J, Romic G, Watts GF (2013) Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies. Curr Atheroscler Rep 15: 309. doi:10.1007/s11883-013-0309-9.